- Investing Ideas
- /
- Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
PharmaEssentia
Market Cap: NT$177.7b
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.
6446
NT$480.50
7D
-4.1%
1Y
-9.8%
Lotus Pharmaceutical
Market Cap: NT$77.3b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$294.00
7D
5.4%
1Y
5.9%